Immuneering Corporation's Role at the Needham Healthcare Conference
Immuneering Corporation, known for its commitment to developing new therapies for cancer, will showcase its groundbreaking work during the 24th Annual Needham Virtual Healthcare Conference. This event is a significant opportunity for Immuneering to share insights about its innovative pipeline and strategies aimed at changing the cancer treatment landscape.
Who Will Represent Immuneering?
The conference will feature key executives from Immuneering, including Ben Zeskind, the CEO, along with other senior leaders such as Brett Hall, the Chief Scientific Officer, and Igor Matushansky, who serves as the Chief Medical Officer. These leaders will engage with investors and peers, highlighting the company’s mission and advancements in oncology therapy.
Presentation Details
Immuneering's presentation is scheduled for April 9, providing an overview of not just its lead product candidate but also other promising therapies in development. The presentation will cover the company’s approach to cancer treatment, emphasizing the need for effective and well-tolerated options for patients.
Immuneering's Innovative Pipeline
At the core of Immuneering’s pipeline is its lead candidate, IMM-1-104. This innovative therapy acts as a once-daily oral deep cyclic inhibitor of MEK. What sets IMM-1-104 apart is its design aimed at enhancing tolerability while broadening treatment options for RAS-driven tumors, including challenging cases like pancreatic cancers. This is crucial as the search for better cancer treatments intensifies.
Current Trials and Future Directions
IMM-1-104 is currently undergoing a Phase 1/2a clinical trial, involving patients with advanced solid tumors. In addition, Immuneering is testing another candidate, IMM-6-415, an oral, twice-daily deep cyclic MEK inhibitor, which is also in a Phase 1/2a trial for patients with solid tumors harboring RAS or RAF mutations. These trials are integral to bringing these innovative therapies to market, aiming to offer more hope for cancer patients.
About Immuneering Corporation
Immuneering is dedicated to transforming the oncology field through its pioneering research and development efforts. With a comprehensive pipeline that includes early-stage programs, the company seeks to address significant unmet needs in cancer treatment. More information on their advancements can be found on their official website, ensuring stakeholders can stay updated on their progress.
Media and Investor Contacts
For those wishing to connect, media inquiries can be directed to Jenna Urban at CGLife, while investors may reach out to Laurence Watts for further information. This open line of communication reflects Immuneering’s commitment to transparency and engagement with both the media and investment communities.
Frequently Asked Questions
What is Immuneering Corporation's primary focus?
Immuneering focuses on developing and commercializing effective and better-tolerated therapies for cancer patients.
When will Immuneering present at the Needham Conference?
The presentation is scheduled for April 9, highlighting their oncology pipeline and business strategies.
What is IMM-1-104?
IMM-1-104 is Immuneering's lead product candidate, designed to be a once-daily oral deep cyclic MEK inhibitor aimed at treating RAS-driven tumors.
How is IMM-6-415 different?
IMM-6-415 is a twice-daily oral deep cyclic MEK inhibitor targeting solid tumors with specific mutations.
Who are the key executives representing Immuneering?
Key executives include CEO Ben Zeskind, Chief Scientific Officer Brett Hall, and Chief Medical Officer Igor Matushansky.
